No studies have performed direct pairwise comparisons of the effectiveness and safety of
warfarin and the new oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban …

Background The introduction of non–vitamin K antagonist oral anticoagulants has been a
major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in …

Background: Apixaban and rivaroxaban are the most commonly prescribed direct oral
anticoagulants for adults with atrial fibrillation, but head-to-head data comparing their safety …

Background The comparative effectiveness and safety of individual direct oral
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …

BACKGROUND: The ARISTOTLE trial demonstrated that apixaban had significantly lower
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …

Background Dabigatran, rivaroxaban, and apixaban have been approved for use in patients
with atrial fibrillation based upon randomized trials demonstrating their comparable or …

Objective: To compare the risk and cost of stroke/systemic embolism (SE) and major
bleeding between each direct oral anticoagulant (DOAC) and warfarin among non-valvular …

Background: Current guidelines recommend using direct oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to …

Background and Purpose—Limited real-world data exist comparing each non–vitamin K
antagonist oral anticoagulant (NOAC) to warfarin in patients with nonvalvular atrial …

Background Whether non–vitamin K antagonist oral anticoagulants (NOAC s) are superior to
warfarin among Asians with nonvalvular atrial fibrillation remains unclear. Methods and …